CEACAM5 was reported to function as an oncogene by promoting tumor progression and inducing anoikis resistance in colorectal cancer, while CEACAM6 was found to be involved in the metastatic process by inducing anoikis resistance in pancreatic cancer (53, 54). Here, CEACAM6 is linked to familial pancreatic carcinoma.